Denali Therapeutics (DNLI) Common Equity (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Common Equity data on file, last reported at $926.1 million in Q1 2026.

• Quarterly Common Equity fell 17.51% year-over-year to $926.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $926.1 million (down 17.51% YoY) and the FY2025 annual result came in at $1.0 billion, down 17.56% from the prior year.
• Common Equity declined to $926.1 million in Q1 2026 per DNLI's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.5 billion in Q1 2024 and bottomed at $811.3 million in Q3 2022.
• The 5-year median for Common Equity is $1.0 billion (2023), against an average of $1.1 billion.
• The widest annual swing landed in 2024, when Common Equity soared 50.56%; it then slipped 29.75% in 2025.
• Tracing DNLI's Common Equity over 5 years: stood at $1.0 billion in 2022, then retreated by 1.1% to $1.0 billion in 2023, then increased by 19.28% to $1.2 billion in 2024, then declined by 17.56% to $1.0 billion in 2025, then dropped by 8.65% to $926.1 million in 2026.
• Per Business Quant, the three latest DNLI Common Equity figures stand at $926.1 million (Q1 2026), $1.0 billion (Q4 2025), and $926.2 million (Q3 2025).

Peer Comparison